All About CARVYKTI (Ciltacabtagene Autoleucel) | a Myeloma BCMA CAR T-Cell Therapy -Updated 2025

In this HealthTree University video, we take a deep dive into CARVYKTI (ciltacabtagene autoleucel) — a cutting-edge CAR T-cell therapy approved for the treatment of relapsed or refractory multiple myeloma. Learn how this personalized immunotherapy works, who it’s intended for, and how it compares to other advanced treatments like Abecma. We’ll walk you through the treatment process from T-cell collection to infusion, discuss key clinical trial results (like the CARTITUDE studies), and explain the potential side effects and monitoring that comes with CARVYKTI. Whether you're navigating treatment options or just want to better understand what CAR T-cell therapy means for myeloma care, this video is for you. Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.